Diabetic peripheral neuropathy (DPN) is one of the most common and consequential complications of diabetes. It develops gradually as chronically elevated blood glucose damages the small and large nerve fibers of the feet and legs, and it is the single most important risk factor on the pathway to foot ulceration and lower-limb amputation. Because the earliest changes are often silent, many people lose protective sensation long before they notice a problem. Understanding how neuropathy is detected and managed is therefore central to preserving mobility and preventing avoidable harm.
Why Diabetic Peripheral Neuropathy Matters
Roughly half of all people with diabetes will develop peripheral neuropathy over the course of their disease, and its presence dramatically raises the likelihood of downstream complications. In their position statement for the American Diabetes Association, Pop-Busui and colleagues describe distal symmetric polyneuropathy — the classic “stocking” distribution beginning in the toes and feet — as the form most strongly linked to foot ulceration, and they emphasize that up to half of cases may be asymptomatic. When sensation is lost, minor trauma from ill-fitting shoes, a pebble, or a callus can go unnoticed until an ulcer forms.
The public-health burden that follows is substantial. A systematic review of Australian populations by Zhang, van Netten, Lazzarini, and colleagues found that among people with diabetes, the prevalence of risk factors such as neuropathy and peripheral artery disease ranged from roughly 10% to 59%, with diabetes-related amputations occurring at an incidence of about 5 to 7 per 1,000 person-years. These figures underscore that neuropathy is rarely an isolated finding — it is a marker of elevated risk for the entire limb.
Detecting Neuropathy Early
Early detection rests on simple, inexpensive bedside tools rather than complex technology. The 10-gram Semmes-Weinstein monofilament remains a cornerstone of screening: the examiner presses the filament against defined sites on the sole until it buckles, and the inability to feel it signals loss of protective sensation. In a study using nerve conduction and autonomic function testing as reference standards, Dube and colleagues confirmed that the 10-gram monofilament is a useful and practical screening instrument for identifying diabetic peripheral neuropathy, though they noted it is best combined with other assessments to improve accuracy.
Comprehensive screening typically pairs the monofilament with tests of vibration perception (using a 128-Hz tuning fork), pinprick and temperature sensation, and ankle reflexes. Current guidance recommends that all people with type 2 diabetes be screened at diagnosis and at least annually thereafter, since a normal examination one year does not guarantee a normal examination the next.
The Case for Acting Sooner
A recurring theme in recent literature is that neuropathy is frequently identified too late. Gad, Kalra, and colleagues, writing in the Journal of the Peripheral Nervous System, issued a “call to action” for earlier diagnosis in primary care, arguing that better recognition of early symptoms and more consistent use of simple screening tools could reduce the number of patients who first present only after complications have developed. Earlier identification allows for earlier intervention, when nerve damage may be more modifiable and protective foot-care habits can be established.
Managing Neuropathy and Its Symptoms
Management of DPN follows two parallel tracks: slowing the underlying nerve damage and treating painful symptoms. The foundation of the first track is glycemic control. Evidence summarized in the American Diabetes Association position statement indicates that intensive glucose management substantially reduces the incidence of neuropathy in type 1 diabetes and modestly slows its progression in type 2 diabetes, alongside attention to blood pressure, lipids, and lifestyle factors.
The second track addresses painful neuropathy, which affects a significant minority of patients and can impair sleep, mood, and quality of life. In a systematic review informing French national recommendations, Moisset and colleagues identified several first-line pharmacologic options for neuropathic pain, including certain antidepressants (such as duloxetine and tricyclics) and anticonvulsants (such as gabapentin and pregabalin), while cautioning against routine use of strong opioids. They also highlighted non-pharmacologic approaches as valuable complements to medication. Importantly, these treatments relieve symptoms but do not reverse the underlying nerve damage, which reinforces the value of prevention and glucose control.
Key Takeaways
Diabetic peripheral neuropathy is common, frequently silent, and a leading precursor to foot ulceration and amputation. It can be screened for reliably with inexpensive tools such as the 10-gram monofilament and tuning fork, and guidelines support annual examination for people with diabetes. Because loss of protective sensation is often the first detectable sign, earlier diagnosis matters. Management combines optimized glycemic and cardiovascular risk control to slow nerve damage with evidence-based pharmacologic and non-pharmacologic strategies to address painful symptoms. Recognizing neuropathy early — before sensation is lost or an ulcer forms — remains one of the most effective ways to protect the diabetic foot.
References
Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi:10.2337/dc16-2042
Zhang Y, van Netten JJ, Baba M, et al. Diabetes-related foot disease in Australia: a systematic review of the prevalence and incidence of risk factors, disease and amputation in Australian populations. Journal of Foot and Ankle Research. 2021;14(1):8. doi:10.1186/s13047-021-00447-x
Dube S, Hulke SM, Wakode SL, et al. Effectiveness of Semmes Weinstein 10 gm monofilament in diabetic peripheral neuropathy taking nerve conduction and autonomic function study as reference tests. Journal of Family Medicine and Primary Care. 2022;11(10):6529–6534. doi:10.4103/jfmpc.jfmpc_195_22
Gad H, Kalra S, Pinzon R, et al. Earlier diagnosis of peripheral neuropathy in primary care: A call to action. Journal of the Peripheral Nervous System. 2024;29(1):28–37. doi:10.1111/jns.12613
Moisset X, Bouhassira D, Avez Couturier J, et al. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Revue Neurologique (Paris). 2020;176(5):325–352. doi:10.1016/j.neurol.2020.01.361
Comments
